Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Clinical trial NCT05479812 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05479812
- Sponsor
- Werewolf Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-20
- Primary completion
- 2026-07-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.